Key result
Low molecular weight heparin was associated with a lower risk of dyslipidemia, including significantly lower triglycerides and higher HDL cholesterol during hemodialysis, compared to high molecular weight heparin.
Why the study?
Cardiovascular disease mortality is elevated in haemodialysis patients, but the comparative effects of low molecular weight heparin versus high molecular weight heparin on lipid profile remained to be evaluated.
Does low molecular weight heparin improve lipid profiles and lipoprotein lipase activity compared to high molecular weight heparin in haemodialysis patients?
Observational (n=60)
Yes
Does low molecular weight heparin improve lipid profiles and lipoprotein lipase activity compared to high molecular weight heparin in haemodialysis patients?
Low molecular weight heparin is associated with a more favorable acute lipid profile and lipoprotein lipase activity during haemodialysis compared to unfractionated heparin.
Answers are grounded in this paper and cite their sources.
Small HD cohort suggests possible lipid differences by heparin type; leaves open need for randomized confirmation before any practice change.
Introduction: In haemodialysis patients, mortality from cardiovascular disease is much greater than in the general population. The current study aimed to evaluate the effects of two different types of heparin, low molecular weight heparins (LMWH) and high molecular weight heparin (HMWH), on lipid profile in patients undergoing haemodialysis.Material & Methods: A total of 60 patients on haemodialysis were selected from two main hospitals of Lahore, Pakistan and were divided into two major groups based on the type of heparin used. A 5 ml blood sample was taken from the dialysis machine to get the serum and was kept frozen at -20ºC for analysis of total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein. Comparison of lipoprotein lipase activity between groups were evaluated by using the student t-test. A P-value of ? 0.05 was considered statistically significant.Results: Gender wise distribution of study population (n=60) was 67% (n=40) males and 33% (n=20) females. The age distribution of individuals varied from 39-43 years. Moreover, use of HMWH was high in males (73%) as compared to female (27%) with an average age of 39 ± 12 years where duration of haemodialysis was 4.44 ± 2.83. A significant difference in LPL activity related to different times in all patients was observed. A clearer difference observed in case of LDL where LPL activity was markedly different in both groups. Our data showed that individuals using LMWH had less chances of dyslipidaemia as compared to those using HMWH.Conclusion: LMWH is a useful and safe anticoagulant during haemodialysis as compared to HMWH.
No takes yet. Share an insight, caveat, or question.
Jan et al. (2021) conducted an observational in End-stage renal disease on haemodialysis (n=60). Low molecular weight heparin (LMWH) vs. High molecular weight heparin (HMWH) / Unfractionated heparin (UFH) was evaluated on Lipoprotein lipase (LPL) activity and lipid profile changes (total cholesterol, triglycerides, HDL, LDL) (p=<0.05). Low molecular weight heparin was associated with a lower risk of dyslipidemia, including significantly lower triglycerides and higher HDL cholesterol during hemodialysis, compared to high molecular weight heparin.
Synapse has enriched 10 related papers. Consider them for comparative context: